Literature DB >> 9287947

Assessment of neutralizing antibodies elicited by a vaccine (Nakayama) strain of Japanese encephalitis virus in Taiwan.

W R Shyu1, Y C Wang, C Chin, W J Chen.   

Abstract

A total of 368 blood specimens were resampled from a serum collection containing 2914 blood samples which were collected by a random sampling in Taiwan in 1991. The plaque reduction neutralization test was applied to evaluate the neutralizing ability to two strains of Japanese encephalitis viruses, i.e. Nakayama (the present vaccine strain) and JE5 (a Taiwan isolate). The result revealed that antibodies against JE virus were present in each stratified age group. Antibody positive rates were both highest in the group older than 70 years although the lowest rates were located in different groups. In addition, the result showed that the immunogenicity potency of the antibody induced by the vaccine strain did not have a good coverage against JE5. The rate of neutralizing antibodies above the level of protective efficacy of the present vaccine was limited as low as 37.93%. Efficacy of the vaccine used at present was apparently not efficient. Consideration of a more promising vaccine may be necessary.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9287947      PMCID: PMC2808826          DOI: 10.1017/s095026889700753x

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  9 in total

1.  E sequence analysis of persistently infected mutant Japanese encephalitis virus strains.

Authors:  Qi Li; Keshu Xu; Huafeng Wang; Xia Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 2.  Japanese encephalitis vaccines: Immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease.

Authors:  Nagendra R Hegde; Milind M Gore
Journal:  Hum Vaccin Immunother       Date:  2017-02-22       Impact factor: 3.452

3.  Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.

Authors:  Yi-Chin Fan; Jo-Mei Chen; Hsien-Chung Chiu; Yi-Ying Chen; Jen-Wei Lin; Chen-Chang Shih; Chih-Ming Chen; Chao-Chin Chang; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

Review 4.  Epidemiology of Japanese encephalitis: past, present, and future prospects.

Authors:  Huanyu Wang; Guodong Liang
Journal:  Ther Clin Risk Manag       Date:  2015-03-19       Impact factor: 2.423

5.  Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area.

Authors:  Lance Turtle; Filippo Tatullo; Tanushka Bali; Vasanthapuram Ravi; Mohammed Soni; Sajesh Chan; Savita Chib; Manjunatha M Venkataswamy; Prachi Fadnis; Mansour Yaïch; Stefan Fernandez; Paul Klenerman; Vijaya Satchidanandam; Tom Solomon
Journal:  PLoS Negl Trop Dis       Date:  2017-01-30

6.  Comparison of JEV neutralization assay using pseudotyped JEV with the conventional plaque-reduction neutralization test.

Authors:  Hee-Jung Lee; Kyung-Il Min; Ki Hoon Park; Hyo Jung Choi; Min-Kyoung Kim; Chi-Young Ahn; Young-Jin Hong; Young Bong Kim
Journal:  J Microbiol       Date:  2014-03-07       Impact factor: 3.422

Review 7.  Japanese encephalitis - the prospects for new treatments.

Authors:  Lance Turtle; Tom Solomon
Journal:  Nat Rev Neurol       Date:  2018-04-26       Impact factor: 42.937

8.  The incidence of Japanese encephalitis in Taiwan--a population-based study.

Authors:  Li-Ching Hsu; Yu-Ju Chen; Feng-Kuang Hsu; Jyh-Hsiung Huang; Chi-Ming Chang; Pesus Chou; I-Feng Lin; Feng-Yee Chang
Journal:  PLoS Negl Trop Dis       Date:  2014-07-24

Review 9.  Japanese encephalitis: the virus and vaccines.

Authors:  Sang-Im Yun; Young-Min Lee
Journal:  Hum Vaccin Immunother       Date:  2013-10-25       Impact factor: 3.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.